Eli Lilly's Slimming Pill Shows Sustained Weight Loss — Here's What the Data Actually Says
Orforglipron (Foundayo) is FDA-approved and new Phase 3 data shows it can maintain weight loss. Here's the full picture.
I now have everything I need. Let me write the article.
A weight-loss pill you can take any time of day — no injections, no fasting-window restrictions — just got a lot more real.
On May 13, 2026, medwatch.com reported that Eli Lilly's oral GLP-1 pill orforglipron — now branded Foundayo™ — is showing sustained weight loss in a new study, adding to a pile of evidence that has been building for over a year. This isn't just another pipeline story. The FDA already approved Foundayo in April 2026, and this latest data is about what happens after the weight comes off.
Here's what you need to know.
What orforglipron actually is
Most GLP-1 receptor agonists on the market right now are injectables — semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) both require a weekly shot. Orforglipron is different: it's a small-molecule GLP-1 receptor agonist taken as a daily pill, and PR Newswire reported in April 2026 that it is the only FDA-approved GLP-1 pill that can be taken any time of day without food or water restrictions — a meaningful difference from earlier oral semaglutide (Rybelsus), which requires a strict 30-minute fasting window.
The mechanism is the same family: it activates GLP-1 receptors to reduce appetite and slow gastric emptying. The delivery is just radically simpler.
What the new study found
The headline-grabbing result comes from the ATTAIN-MAINTAIN trial (NCT06584916), a completed Phase 3 study listed on ClinicalTrials.gov. Its stated purpose: evaluate whether orforglipron can maintain body weight reduction in people with obesity or overweight with weight-related health conditions. The BBC reported on May 12 that this is a "daily pill to help keep weight off after stopping obesity jabs" — meaning the trial specifically tested whether orforglipron could hold the line after people transitioned off injectable GLP-1s.
That's the part that matters. Regain after stopping GLP-1 injections is a well-documented problem. A maintenance pill that's easier to stay on could change the long-term math for a lot of people.
What the earlier efficacy data showed
The new maintenance study builds on a foundation of solid Phase 2 and Phase 3 efficacy data. A 2023 New England Journal of Medicine trial of daily oral orforglipron in adults with obesity — the GZGI trial — showed meaningful weight loss compared to placebo. Then, the full ATTAIN-1 Phase 3 results, published in the New England Journal of Medicine in November 2025, confirmed those results in a larger population, with the ATTAIN-1 investigators reporting efficacy and safety data for orforglipron as an obesity treatment.
A systematic review and meta-analysis published in Metabolism also pooled data across randomized controlled trials of oral small-molecule GLP-1 agonists including orforglipron, finding favorable safety and efficacy signals across the class.
The Guardian reported in February 2026 that a GLP-1 pill helped patients lose up to 8% of body weight in trial data — a figure that, while not as dramatic as the 15–20%+ seen with injectable tirzepatide, is still clinically meaningful. MedlinePlus notes that obesity raises risk for type 2 diabetes, heart disease, kidney disease, and certain cancers — so even moderate sustained loss carries real health implications.
Why the pill format is a bigger deal than it sounds
Needle aversion is real, and it's one of the top reasons people don't start or stay on injectable GLP-1 therapy. A pill removes that barrier entirely. It also removes the cold-chain storage requirement (injectables need refrigeration), which matters for travel and access.
CNBC noted in January 2026 that 2026 is shaping up as "the year of obesity pills," with orforglipron setting up fierce competition with Novo Nordisk's injectable franchise. STAT News reported that the FDA approval of Foundayo is already setting up that competitive battle.
What this means for you
- Orforglipron (Foundayo™) is now FDA-approved and available by prescription — if you've avoided GLP-1 therapy because of the injections, this is worth a conversation with your prescriber.
- The maintenance angle is new and important. The ATTAIN-MAINTAIN trial data suggests the pill may help people hold their weight loss after stopping injectables — but discuss what that transition looks like with your doctor, because individual results vary.
- It's not a magic upgrade over injectables. The weight-loss percentage seen in trials appears lower than what's reported with tirzepatide. What you gain is convenience and accessibility — that trade-off is yours to weigh with your care team.
Not medical advice. Talk to your prescriber about your specific situation, health history, and whether orforglipron is right for you.
